search
Back to results

DETECT-IP: a Clinical Decision Support System and Intelligent Procedures to Counter Some Adverse Drug Events in Older Hospital Patients (DETECT-IP:)

Primary Purpose

Patient Acceptance of Health Care, Acute Renal Failure

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Clinical decision support
Will not receive Clinical Decision Support
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Patient Acceptance of Health Care focused on measuring Acute renal failure, hyperkaliemia, older people, computerized decision support system, stepped-wedge

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Hospitalized for 3 days or more in an MCO (medicine surgery obstetrics) department participating in the study Patient who gave oral consent to participate in the study Socially insured patient Exclusion Criteria: Patient discharged or died before D3 of hospitalization Patient in palliative care or end of life on entry to the service Person under legal protection (curatorship) Lack of coverage by the social security system, Failure to obtain oral consent to participate in the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Intervention Group

    Control Group

    Arm Description

    Outcomes

    Primary Outcome Measures

    Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients.

    Secondary Outcome Measures

    Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug")
    Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission
    Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug
    Relevance of CDSS alerts
    Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687
    Number of pharmaceutical interventions accepted
    When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop
    Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts
    Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods.
    Cost-effectiveness of the pharmaceutical intervention
    Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention

    Full Information

    First Posted
    February 9, 2023
    Last Updated
    June 26, 2023
    Sponsor
    University Hospital, Lille
    Collaborators
    OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations, Regional Agency of Sante Nord Pas-de-Calais
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05923983
    Brief Title
    DETECT-IP: a Clinical Decision Support System and Intelligent Procedures to Counter Some Adverse Drug Events in Older Hospital Patients
    Acronym
    DETECT-IP:
    Official Title
    Reduction of Acute Renal Failure and/or Hyperkaliemia Adverse Drug Events in Older Inpatients by Incorporating Specific Rules Into a Computerized Support System and Dedicated Procedures: a Randomized Trial.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 2023 (Anticipated)
    Primary Completion Date
    July 2024 (Anticipated)
    Study Completion Date
    July 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Lille
    Collaborators
    OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations, Regional Agency of Sante Nord Pas-de-Calais

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption. The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Patient Acceptance of Health Care, Acute Renal Failure
    Keywords
    Acute renal failure, hyperkaliemia, older people, computerized decision support system, stepped-wedge

    7. Study Design

    Primary Purpose
    Health Services Research
    Study Phase
    Not Applicable
    Interventional Study Model
    Sequential Assignment
    Model Description
    Prospective, multicentre, controlled, single-blind, randomised cluster study with stepped-wedge permutations. The centres (hospitals) will be the clusters.
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    4920 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention Group
    Arm Type
    Experimental
    Arm Title
    Control Group
    Arm Type
    Other
    Intervention Type
    Other
    Intervention Name(s)
    Clinical decision support
    Intervention Description
    In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
    Intervention Type
    Other
    Intervention Name(s)
    Will not receive Clinical Decision Support
    Intervention Description
    In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
    Primary Outcome Measure Information:
    Title
    Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients.
    Time Frame
    through study completion, an average of 20 days
    Secondary Outcome Measure Information:
    Title
    Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug")
    Time Frame
    through study completion, an average of 20 days
    Title
    Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission
    Description
    Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug
    Time Frame
    through study completion, an average of 15 days
    Title
    Relevance of CDSS alerts
    Description
    Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687
    Time Frame
    through study completion, an average of 20 days
    Title
    Number of pharmaceutical interventions accepted
    Description
    When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop
    Time Frame
    through study completion, an average of 20 days
    Title
    Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts
    Description
    Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods.
    Time Frame
    Through study completion, an average of 20 days
    Title
    Cost-effectiveness of the pharmaceutical intervention
    Description
    Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention
    Time Frame
    through study completion, an average of 20 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Hospitalized for 3 days or more in an MCO (medicine surgery obstetrics) department participating in the study Patient who gave oral consent to participate in the study Socially insured patient Exclusion Criteria: Patient discharged or died before D3 of hospitalization Patient in palliative care or end of life on entry to the service Person under legal protection (curatorship) Lack of coverage by the social security system, Failure to obtain oral consent to participate in the study
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jean-Baptiste Beuscart, MD
    Phone
    0320445962
    Ext
    +33
    Email
    jean-baptiste.beuscart@univ-lille.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jean-Bapstiste Beuscart, MD
    Organizational Affiliation
    University Hospital, Lille
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    DETECT-IP: a Clinical Decision Support System and Intelligent Procedures to Counter Some Adverse Drug Events in Older Hospital Patients

    We'll reach out to this number within 24 hrs